Analysts expect Impax Laboratories, Inc. (NASDAQ:IPXL) to post $198.42 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Impax Laboratories’ earnings. The lowest sales estimate is $192.52 million and the highest is $204.30 million. Impax Laboratories also posted sales of $198.42 million in the same quarter last year. The business is expected to announce its next earnings report on Wednesday, March 7th.

On average, analysts expect that Impax Laboratories will report full year sales of $198.42 million for the current year, with estimates ranging from $773.61 million to $810.00 million. For the next fiscal year, analysts forecast that the company will post sales of $843.92 million per share, with estimates ranging from $797.70 million to $881.48 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Impax Laboratories.

Impax Laboratories (NASDAQ:IPXL) last released its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.03. The business had revenue of $206.40 million for the quarter, compared to the consensus estimate of $208.38 million. Impax Laboratories had a negative net margin of 56.59% and a positive return on equity of 9.06%. The company’s revenue was down 9.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.37 earnings per share.

Several equities research analysts have commented on IPXL shares. Cantor Fitzgerald set a $20.00 price objective on shares of Impax Laboratories and gave the company a “buy” rating in a report on Wednesday, August 9th. Cowen set a $20.00 price objective on shares of Impax Laboratories and gave the company a “hold” rating in a report on Wednesday, August 9th. Canaccord Genuity set a $19.00 price target on shares of Impax Laboratories and gave the stock a “hold” rating in a report on Wednesday, August 9th. Piper Jaffray Companies set a $17.00 price target on shares of Impax Laboratories and gave the stock a “hold” rating in a report on Thursday, August 10th. Finally, Royal Bank Of Canada set a $17.00 price target on shares of Impax Laboratories and gave the stock a “hold” rating in a report on Thursday, August 10th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $19.60.

Impax Laboratories (NASDAQ:IPXL) traded up $0.10 during midday trading on Monday, reaching $16.75. 658,100 shares of the company’s stock traded hands, compared to its average volume of 1,805,992. The stock has a market capitalization of $1,241.40, a P/E ratio of 24.63, a PEG ratio of 1.06 and a beta of 0.94. Impax Laboratories has a 1-year low of $7.75 and a 1-year high of $25.70. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.32 and a current ratio of 1.81.

Institutional investors have recently made changes to their positions in the company. Maverick Capital Ltd. raised its stake in Impax Laboratories by 6,705.5% in the second quarter. Maverick Capital Ltd. now owns 7,159,336 shares of the specialty pharmaceutical company’s stock valued at $115,265,000 after purchasing an additional 7,054,136 shares in the last quarter. Fosun International Ltd raised its stake in Impax Laboratories by 1,185.0% in the third quarter. Fosun International Ltd now owns 3,854,995 shares of the specialty pharmaceutical company’s stock valued at $78,256,000 after purchasing an additional 3,554,995 shares in the last quarter. Fisher Asset Management LLC purchased a new stake in Impax Laboratories in the third quarter valued at approximately $30,329,000. Janus Henderson Group PLC purchased a new stake in Impax Laboratories in the third quarter valued at approximately $28,573,000. Finally, Balyasny Asset Management LLC raised its stake in Impax Laboratories by 357.7% in the second quarter. Balyasny Asset Management LLC now owns 1,051,484 shares of the specialty pharmaceutical company’s stock valued at $16,929,000 after purchasing an additional 821,734 shares in the last quarter. 90.79% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/04/198-42-million-in-sales-expected-for-impax-laboratories-inc-ipxl-this-quarter.html.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Get a free copy of the Zacks research report on Impax Laboratories (IPXL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.